首页 >
法规速递
-
关于将Vorasidenib纳入“儿童抗肿瘤药物研发鼓励试点计划（星光计划）”试点项目的通知-2025/12/1
2025-12-02查看详情 > -
国家药监局综合司公开征求《医疗器械复检机构遴选规定（征求意见稿）》意见 -2025/12/31
2026-01-03查看详情 > -
Document: Guideline on good pharmacovigilance practices (GVP): Product- or population-specific considerations III: Pregnant and breastfeeding women and their children exposed in utero or via breastmilk - with tracked changes-2026/2/6
2026-02-09查看详情 > -
Page: Clinical pharmacology and pharmacokinetics: questions and answers-2026/3/17
2026-03-18查看详情 > -
Page: Respiratory syncytial virus (RSV)-2026/4/20
2026-04-21查看详情 > -
Document: Questions and answers on the refusal of a change to the marketing authorisation for Hetlioz (tasimelteon) (II-40)-2026/6/2
2026-06-03查看详情 > -
Document: Scientific advice and protocol assistance adopted during the CHMP meeting 22-25 June 2026-2026/7/15
2026-07-16查看详情 > -
国家药监局药审中心关于发布《急性髓系白血病新药临床研发技术指导原则》的通告（2023年第3号）-2023/02/13
2023-02-13查看详情 > -
Regulatory and procedural guideline: Member states contact points for translations review (updated)-2023/8/30
2023-09-01查看详情 > -
国家药监局关于发布《药品生产质量管理规范（2010年修订）》药用辅料附录、药包材附录的公告（2025年第1号）-2025/1/2
2025-01-03查看详情 >
